Asymptomatic carotid stenosis: What we can learn from the next generation of randomized clinical trials
JRSM Cardiovascular Disease · 2014
DOI: 10.1177/2048004014529419 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JRSM Cardiovascular Disease, 2014. Verfasst von Mark N Rubin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Department of Neurology, Jacksonville, FL, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Stroke remains an exceedingly incident and prevalent public health burden across the globe, with an estimated 16 million new strokes per annum and prevalence over 60 million, and extracranial internal carotid artery atherosclerotic disease is an important risk factor for stroke. Randomized trials of surgical treatment were conducted (North American Symptomatic Carotid Endarterectomy Trial, European Carotid Surgery Trial) and demonstrated efficacy of carotid endarterectomy for secondary prevention of stroke in patients with cerebrovascular events (e.g. ipsilateral stroke, transient ischemic attack, and/or amaurosis fugax) attributable to a diseased artery with 50–99% stenosis. Therapeutic clarity, however, proved elusive with asymptomatic carotid artery disease. Asymptomatic Carotid Atherosclerosis Study (ACAS), Asymptomatic Carotid Surgery Trial, and Veterans Affairs Cooperative Study (VACS) suggested only modest benefit from surgical intervention for primary stroke prevention and the best medical therapy at the time of these trials is not comparable to modern medical therapy. ACT-1, Asymptomatic Carotid Surgery Trial-2, Stent-Protected Angioplasty in asymptomatic Carotid artery stenosis versus Endarterectomy Trial-2, European Carotid Surgery Trial-2, Carotid Revascularization Endarterectomy Versus Stenting Trial-2 are trials that are recent, ongoing, or in development that include diverse populations across Europe and North America, complementary trial designs, and a collaborative spirit that should provide clinicians with evidence that informs best clinical practice for asymptomatic carotid artery disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mayo Clinic, Department of Neurology, Jacksonville, FL, USA.
Zitieren
APA
Rubin, M. N., Barrett, K. M., Brott, T. G., & Meschia, J. F. (2014). Asymptomatic carotid stenosis: What we can learn from the next generation of randomized clinical trials. JRSM Cardiovascular Disease. https://doi.org/10.1177/2048004014529419
Vancouver
Rubin MN, Barrett KM, Brott TG, Meschia JF. Asymptomatic carotid stenosis: What we can learn from the next generation of randomized clinical trials. JRSM Cardiovascular Disease. 2014. doi:10.1177/2048004014529419
BibTeX
@article{Rubin2014,
author = {Rubin, Mark N and Barrett, Kevin M and Brott, Thomas G and Meschia, James F},
title = {Asymptomatic carotid stenosis: What we can learn from the next generation of randomized clinical trials},
journal = {JRSM Cardiovascular Disease},
year = {2014},
doi = {10.1177/2048004014529419}
}
EUVIMED